Sharing risk between payer and provider by leasing health technologies: An affordable and effective reimbursement strategy for innovative technologies?

Value in Health

Volumn 17, Issue 4, 2014, Pages 438-444

  Edlin, Richard ^a   Hall, Peter ^b   Wallner, Klemens ^c   McCabe, Christopher ^c  

^a UNIVERSITY OF AUCKLAND   (New Zealand)

^b UNIVERSITY OF LEEDS   (United Kingdom)

^c UNIVERSITY OF ALBERTA   (Canada)

Author keywords

cost effectiveness; decision uncertainty; risk; value based pricing

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; TRASTUZUMAB;

ACCESS WITH EVIDENCE DEVELOPMENT; ARTICLE; BREAST CANCER; BUDGET; CLINICAL PRACTICE; COST EFFECTIVENESS ANALYSIS; EARLY CANCER; ELECTRONIC MEDICAL RECORD; HEALTH CARE ACCESS; HEALTH CARE COST; HEALTH CARE DELIVERY; HEALTH CARE PERSONNEL; HEALTH CARE POLICY; HEALTH CARE SYSTEM; HUMAN; INVESTMENT; LEASING; LONG TERM CARE; MEDICAL FEE; MEDICAL TECHNOLOGY; NUCLEAR MAGNETIC RESONANCE SCANNER; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; REIMBURSEMENT; ROBOTICS; TECHNOLOGY LEASING REIMBURSEMENT STRATEGY; VALUE BASED PRICING;

COST EFFECTIVENESS; DECISION UNCERTAINTY; RISK; VALUE-BASED PRICING;

ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; BIOMEDICAL TECHNOLOGY; COST-BENEFIT ANALYSIS; DIFFUSION OF INNOVATION; HUMANS; LEASING, PROPERTY; REIMBURSEMENT MECHANISMS; RISK SHARING, FINANCIAL; TIME FACTORS;

EID: 84903306293     PISSN: 10983015     EISSN: 15244733     Source Type: Journal    
DOI: 10.1016/j.jval.2014.01.010     Document Type: Article

References (18)

1. S. Walker, M. Sculpher, K. Claxton, and S. Palmer Coverage with evidence development, only in research, risk sharing, or patient access scheme? A framework for coverage decisions Value Health 15 2012 570 579
2. Department of Health, Medicines, Pharmacy & Industry Group. A new value based approach to the pricing of branded medicines: government response to consultation. 2011. Available from: http://webarchive.nationalarchives.gov.uk/ 20130107105354/http://www.dh.gov.uk/prod-consum-dh/groups/dh-digitalassets/ documents/digitalasset/dh-128404.pdf. [Accessed April 16, 2014].
3. T. Stafinski, C. McCabe, and D. Menon Funding the unfundable: mechanisms for managing uncertainty in decisions on the introduction of new and innovative technologies into healthcare systems Pharmacoeconomics 28 2010 113 142
4. C. McCabe, T. Stafinski, R. Edlin, and D. Menon Access with evidence development schemes: a framework for description and evaluation Pharmacoeconomics 28 2010 143 152
5. K. Claxton, A. Briggs, and M.J. Buxton et al. Value based pricing for NHS drugs: an opportunity not to be missed? BMJ 336 2008 251 254
6. P.S. Hall, R.P. Edlin, and S. Kharroubi et al. Expected net present value of sample information: from burden to investment Med Decis Making 32 2012 E11 E21
7. C. McCabe, K. Claxton, and A.J. Culyer The NICE cost-effectiveness threshold: what it is and what that means Pharmacoeconomics 26 2008 733 744
8. GE Capital Aviation Services. Aircraft leasing and financing solutions. 2011. Available from: http://www.gecas.com/en/engine.html. [Accessed April 16, 2014].
9. C. McCabe, and P. Hall Navigating time and uncertainty in cost-effectiveness appraisal: would a map help? Pharmacoeconomics 31 2013 731 737
10. P. Hall, C. Hulme, and C. McCabe et al. Updated cost-effectiveness analysis of trastuzumab for early breast cancer: a UK perspective considering duration of benefit, long-term toxicity and pattern of recurrence Pharmacoeconomics 29 2011 415 432
11. Claxton K, Martin S, Soares M, et al. Methods for the estimation of the NICE cost effectiveness threshold. CHE Research Paper 81. 2013. Available from: http://www.york.ac.uk/media/che/documents/papers/researchpapers/ CHERP81-Methods-estimation-NICE-costeffectiveness-threshold.pdf. [Accessed April 16, 2014].
12. National Institute for Health and Care Excellence. Guide to the methods of health technology appraisal. 2008. Available from: http://www.nice.org.uk/ media/B52/A7/TAMethodsGuideUpdatedJune2008.pdf. [Accessed April 16, 2014].
13. L. Rochaix, and B. Xerri Issue Brief (Commonwealth Fund) 58 2009 1 9
14. S. Jaroslowski, and M. Toumi Market access agreements for pharmaceuticals in Europe: diversity of approaches and underlying concepts BMC Health Serv Res 11 2011 259
15. J.J. Carlson, S.D. Sullivan, and L.P. Garrison et al. Linking payment to health outcomes: A taxonomy and examination of performance-based reimbursement schemes between healthcare payers and manufacturers Health Policy 96 2010 179 190
16. N. Daniels Accountability for reasonableness BMJ 321 2000 1300
17. King, I. Not very nice for anybody: Business Editors Commentary. The Times. August 30, 2013.
18. Dillon A. NICE responds to article in The Times. National Institute for Health and Care Excellence. 2013. Available from: http://www.nice.org.uk/ newsroom/news/NICERespondsToArticleInTheTimes.jsp. [Accessed September 6, 2013].